Latest data from the Hong Kong Stock Exchange reveals that on January 20, a shareholder of TOUYUN BIOTECH (01332) transferred shares from Wutong Securities to KGI Asia. The transferred portfolio was valued at HK$35.35 million, representing 5.04% of the company's shares.

TOUYUN BIOTECH previously announced its interim results for the six months ended June 30, 2025. The group reported revenue of HK$36.581 million from sales of goods and services provided, a decrease of 20.82% compared to the same period last year. Profit attributable to the company's owners was HK$11.243 million, a significant turnaround from a loss of HK$47.969 million in the prior year period. Earnings per share stood at 0.4 HK cents.